Profile

Wayne Morgan

Professor, Physiology | Associate Director, Asthma / Airway Disease Research Center | Professor, Pediatrics | Member of the Graduate Faculty

Collaboration(51)

Page 1 of 11

Grants(37)

Page 1 of 8

Publications(85)

Recent

Additional Thoughts on Intrinsic Dysanapsis

2024

Association of Sputum Eosinophilia With Easily Measured Type-2 Inflammatory Biomarkers in Untreated Mild Persistent Asthma

2024

Childhood asthma exacerbations on the Navajo Nation

2024

Circulating biomarkers of airflow limitation across the life

2024

Impact of Viral Lower Respiratory Tract Infection LRTI) in Early Childhood 0-2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health NIH) WorkshoSummary

2024

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA

2024

Omitting placebos from early-stage clinical trials of cystic fibrosis therapies.

2024

The 25-year experience of the cystic fibrosis foundation data safety monitoring board.

2024

The impact of switching to race-neutral reference equations on FEV percent predicted among people with cystic fibrosis

2024

Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF

2024

Profile

Wayne Morgan

Collaboration(51)

Sairam Parthasarathy

Kenneth Knox

Walter Klimecki

Fernando Martinez

Teshia Solomon

Grants(37)

Publications(85)

Additional Thoughts on Intrinsic Dysanapsis

Association of Sputum Eosinophilia With Easily Measured Type-2 Inflammatory Biomarkers in Untreated Mild Persistent Asthma

Childhood asthma exacerbations on the Navajo Nation

Circulating biomarkers of airflow limitation across the life

Impact of Viral Lower Respiratory Tract Infection LRTI) in Early Childhood 0-2 Years) on Lung Growth and Development and Lifelong Trajectories of Pulmonary Health: A National Institutes of Health NIH) WorkshoSummary

Impact of the expanded label for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del variant in the USA

Omitting placebos from early-stage clinical trials of cystic fibrosis therapies.

The 25-year experience of the cystic fibrosis foundation data safety monitoring board.

The impact of switching to race-neutral reference equations on FEV percent predicted among people with cystic fibrosis

Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF